Each innovator selected was chosen for their commitment to addressing health care challenges and their sheer brilliance in their subjects. Photo via Getty Images

A group of seven groundbreaking scientists has been chosen as the first cohort of a top-flight new program for medical innovators.

Last year, the National Institute of Health (NIH) awarded the Gulf Coast Consortium with a $4 million grant. Its use? The Research Evaluation and Commercialization Hub, known as REACH. REACH combines the powers of one of the world’s largest inter-institutional cooperatives — including eight Houston-area medical research organizations— to help accelerate fledgling innovations.

According to program manager Lacey Tezino, REACH received 31 applications over the course of a month last fall.

“They were really solid applications. I was just like, ‘Can we take all of them?’” Tezino tells InnovationMap.

The seven successful applicants were chosen through technology feedback forums led by experts in each field represented. According to Tezino, some of the industry and subject-matter experts went on to become mentors to the members of the first cohort, while others were simply too busy to contribute more of their time.

But the seven teams that were selected can rest assured that they’re in spectacular hands.

“When you are bringing a novel technology to us, I can find someone who is an expert in almost anything that you're doing within health care technology — everyone's at our fingertips. So when it comes to getting advisors, because we're in the Texas Medical Center, the network that we have in the ecosystem is so rich with health care technology, that the support that those who apply for REACH is sort of unmatched,” Tezino says.

Even more impressive, Tezino explains that there are NIH officers waiting to review the projects. For early-stage entrepreneurs, that means that they will be pushed to gain what will likely be their first NIH and SBIR (small business innovation research) grants.

“We get their plan together and then we basically put them on a platter for the NIH,” says Tezino.

Each innovator selected was chosen for their commitment to addressing health care challenges and their sheer brilliance in their subjects, says Tezino. They include:

  • Fernanda Laezza, from the University of Texas Medical Branch, who is seeking to create next-generation pain medications by developing small-molecule drugs.
  • Robert Y. Tsai, from Texas A&M University Institute for Biosciences and Technology, who is testing a medicated, mucoadhesive patch as a non-invasive treatment of oral precancers.
  • Jean X. Jiang and Johanna Webb, from Riverwalk Therapeutics in San Antonio, who are working on new treatments for metastatic cancer and fibrotic retinal diseases.
  • Nadia German, from Texas Tech University, who seeks to treat triple-negative breast cancer and neuropathic pain with novel drugs.
  • Daniel Diaz and his team at Intelligent Proteins in Houston, who are using AI tools to engineer new proteins for use in cancer treatments.
  • From Texas A&M University, Thomas Kent is developing oxidized carbon nanoparticles to treat mitochondrial diseases, including Friedreich’s ataxia.
  • Mario Escobar, from Rice University, who is advancing a novel biologic gene therapy to treat heart failure.

The REACH program lasts nine months, but before the end of that time, the GCC will have recruited and begun working with the next cohort. Interested scientists can apply for the program on a rolling basis at GCCREACH.org. Tezino says that GCC plans to work with three cohorts a year, so there are ample opportunities for qualified candidates.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New CEO brings strategic vision to Houston co. advancing neurodegenerative disease treatments

Q&A

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

“(Berman's) intent was that it was the right time to put in place a CEO that, as we move into the operational phases of the company, that can take the reins from him,” he tells InnovationMap.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients.

InnovationMap: Berman has been a very visible CEO. Will you follow suit?

Arun Swaminathan: I think it's part of the CEO’s job to be visible and to communicate the value of our company to all the stakeholders out there. So yes, I do plan to be visible as well. Obviously, Howard as the founder had elements that he talked about, the foundational stories. I obviously will be doing less of that.

IM: What was your journey from the lab to the boardroom?

AS: I have a PhD from the University of Pittsburgh. I like to say that I grew up at Bristol Myers Squibb, so I started in a clinical pharmacology group at BMS, running clinical trials, but in the cardiovascular and metabolic space.

What happened was, as I was the study director on a diabetes trial there, and the data starts coming in for these early diabetic trials, and I got highly involved with the commercial folks at BMS in starting to plan out “What does the target profile look like? How is this going to play out in the real world?” You know, the marketing teams and commercial teams start engaging when clinical data is available, because they're starting to plan for the eventual launch of the product.

That gave me a lot of exposure to the commercial side of things, and I also got a lot of experience presenting to opinion leaders and others through that role. And I said, “What I really love is that intersection between science and business.” And so I think that was my moment.

Then I moved to business development and licensing, where I helped scan the universe for assets and talk to CEOs of companies like Coya as a junior person, trying to understand if there's something that we can bring into BMS to strengthen the pipeline of BMS. So that gave me exposure to deals, how deals are structured, how you negotiate a lot of that kind of stuff.

Then I said, “Look, if I want to be a complete person in biotech, I do need to go into more true commercial roles.” So I went into commercial strategy. I was involved in the commercial strategy for what is now known as Eliquis. Was back then known as apixaban. That’s still the generic name.

Then I led marketing for Orencia, a rheumatoid arthritis drug. So I went and got both strategic and tactical marketing experience at BMS, and then I used all of that experience, rounded up. I eventually ended up co-founding a company, and that's led me to the last nine years with smaller biotech companies. So that's my evolution and path. But I think my true moment of realization was about three years into my clinical role at BMS, when I said, what I really enjoy is translating good science into commercial value, and I think that's what excites me.

IM: Why is Houston an important part of Coya's success?

AS: It is important that Coya stays in Houston, because we have a very close association with Houston Methodist, we get a lot of our work, our early research work still done through Houston Methodist, through Dr. [Stanley] Appel's lab and through other experts. We absolutely have a special research agreement with Houston Methodist, so we have a very strong reason to be in Houston. So, we do not anticipate moving out of Houston.

------

This conversation has been edited for brevity and clarity.

California femtech leader integrates Houston-founded conversational AI tool

girl gang

Willow users, meet Ema — you're new best AI-enabled friend.

Houston-founded Ema (née SocialMama), an AI resource for maternal health support, has been loaded onto the Willow Innovations Inc. app, a platform for breastfeeding mothers.

"We are thrilled to integrate our conversational AI platform into the Willow App and leverage the power of advanced technology to meet women where they are with the information they need," Amanda Ducach, founder of Ema, says in a news release. "Ema and Willow have a shared mission to make lasting improvements in women's health and we built a one-of-a-kind solution that addresses the unique challenges mothers face regularly.

"Our partnership represents a critical advancement for today's mothers and demonstrates how responsible AI can improve the maternal care experience," she continues.

Now, users on the app can utilize Ema's HIPPA-secure tool that pulls from a comprehensive, proprietary database of expert-backed information. The conversational AI chatbot responds prioritizing speed, accuracy, and empathy and compassion for users. Ema reports that their users "will feel like they are talking with their favorite postpartum (labor and delivery) nurse."

"New moms don't have enough support — for their feeding and parenting journey, or in their postpartum care. We're thrilled to partner with Ema to offer moms personalized information along this journey," adds Sarah O'Leary, CEO of Willow. "AI tools, when implemented thoughtfully, can help close gaps in delivering personalized guidance at an efficient scale and I'm excited about the impact Ema can have on the well-being of mothers in our Willow community."

Founded in 2018 as a way to connect new moms, Ema evolved with a major rebrand and pivot to AI-backed tools last year.

Willow was launched in 2014 and released the first wearable, in-bra breast pump in 2017.

Houston researchers find alternate data for loan qualification

houston voices

Millions of consumers who apply for a loan to buy a house or car or start a business can’t qualify — even if they’re likely to pay it back. That’s because many lack a key piece of financial information: a credit score.

The problem isn’t just isolated to emerging economies. Exclusion from the financial system is a major issue in the United States, too, where some 45 million adults may be denied access to loans because they don’t have a credit history and are “credit invisible.”

To improve access to loans and peoples’ economic mobility, lenders have started looking into alternative data sources to assess a loan applicant’s risk of defaulting. These include bank account transactions and on-time rental, utility and mobile phone payments.

A new article by Rice Business assistant professor of marketing Jung Youn Lee and colleagues from Notre Dame and Northwestern identifies an even more widespread data source that could broaden the pool of qualified applicants: grocery store receipts.

As metrics for predicting credit risk, the researchers found that the types of food, drinks and other products consumers buy, and how they buy them, are just as good as a traditional credit score.

“There could be privacy concerns when you think about it in practice,” Lee says, “so the consumer should really have the option and be empowered to do it.” One approach could be to let consumers opt in to a lender looking at their grocery data as a second chance at approval rather than automatically enrolling them and offering an opt-out.

To arrive at their findings, the researchers analyzed grocery transaction data from a multinational conglomerate headquartered in a Middle Eastern country that owns a credit card issuer and a large-scale supermarket chain. Many people in the country are unbanked. They merged the supermarket’s loyalty card data and issuer’s credit card spending and payment history numbers, resulting in data on 30,089 consumers from January 2017 to June 2019. About half had a credit score, 81% always paid their credit card bills on time, 12% missed payments periodically, and 7% defaulted.

The researchers first created a model to establish a connection between grocery purchasing behavior and credit risk. They found that people who bought healthy foods like fresh milk, yogurt and fruits and vegetables were more likely to pay their bills on time, while shoppers who purchased cigarettes, energy drinks and canned meat tended to miss payments. This held true for “observationally equivalent” individuals — those with similar income, occupation, employment status and number of dependents. In other words, when two people look demographically identical, the study still finds that they have different credit risks.

People’s grocery-buying behaviors play a factor in their likelihood to pay their bills on time, too. For example, cardholders who consistently paid their credit card bill on time were more likely to shop on the same day of the week, spend similar amounts across months and buy the same brands and product categories.

The researchers then built two credit-scoring predictive algorithms to simulate a lender’s decision of whether or not to approve a credit card applicant. One excludes grocery data inputs, and the other includes them (in addition to standard data). Incorporating grocery data into their decision-making process improved risk assessment of an applicant by a factor of 3.11% to 7.66%.

Furthermore, the lender in the simulation experienced a 1.46% profit increase when the researchers implemented a two-stage decision-making process — first, screening applicants using only standard data, then adding grocery data as an additional layer.

One caveat to these findings, Lee and her colleagues warn, is that the benefit of grocery data falls sharply as traditional credit scores or relationship-specific credit histories become available. This suggests the data could be most helpful for consumers new to credit.

Overall, however, this could be a win-win scenario for both consumers and lenders. “People excluded from the traditional credit system gain access to loans,” Lee says, “and lenders become more profitable by approving more creditworthy people.”

------

This article originally ran on Rice Business Wisdom based on research by Rice University's Jung Youn Lee, Joonhyuk Yang (Notre Dame) and Eric Anderson (Northwestern). “Using Grocery Data for Credit Decisions.” Forthcoming in Management Science. 2024: https://doi.org/10.1287/mnsc.2022.02364.